GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

British pharmaceutical company GSK reported on Wednesday that its third-quarter profit before tax dropped to £64 million ($83 ...

GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Shares of GSK PLC GSK dropped 1.59% to £13.92 Tuesday, on what proved to be an all-around poor trading session for the stock ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024 GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while ...

India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...

(Reuters) - GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine ...